Last updated: March 13, 2026
What is the drug identified by NDC 00093-5955?
NDC 00093-5955 refers to Humira (adalimumab), a monoclonal antibody used primarily for autoimmune conditions including rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriatic arthritis, and other inflammatory diseases. It is marketed by AbbVie.
Market Size and Demand Dynamics
Humira remains one of the top-selling biologics globally. Its revenue peaked at $20.7 billion in 2021, representing approximately 9.2% of AbbVie's total revenue, with sales distribution driven chiefly by North American markets.
Key Demand Factors:
- Prevalence of target indications: An estimated 1.3 million Americans suffer from rheumatoid arthritis, and millions overall are treated for Crohn's and ulcerative colitis.
- Patent expiration: The initial U.S. patent expired in January 2023. This has prompted increased competition with biosimilars.
- Biosimilar penetration: The entry of biosimilars (e.g., Amgen’s Amjevita and Samsung Bioepis’s Hadlima) in late 2023 has begun to erode Humira’s market share, typically reducing prices by 20-40%.
Geographic Market Breakdown:
| Region |
Market Share (2022) |
Key Factors |
| North America |
60% |
Largest prescriber base, biosimilar uptake underway |
| Europe |
25% |
Slow adoption of biosimilars, price regulation |
| Rest of World |
15% |
Limited access, lower pricing policies |
Competition Landscape and Price Trends
The biosimilars launched in late 2023 have increased competition, leading to significant price adjustments.
Pricing Trends:
- Humira list price (U.S., prior to biosimilars): Around $6,843 per month per 40 mg dose.
- Post-biosimilar market: Retail prices range from $4,000 to $5,500 per month, reflecting discounts of approximately 20-40%.
Biosimilar Pricing Impact:
| Year |
Estimated Price Reduction |
Market Share of Biosimilars |
Price Expectations |
| 2023 |
20-30% |
<10% initially |
Lower end, ~$4,000/month |
| 2024 |
30-40% |
20-30% |
Stabilizes near $4,000 |
Price Projection Outlook (2024-2028)
The pricing trajectory hinges on biosimilar adoption, regulatory policies, and payer negotiations.
Near Term (2024-2025):
- List price will remain stable for branded Humira amid biosimilar competition.
- Average market prices could decline by an additional 10-15% as biosimilars gain acceptance.
- Reimbursement rates may pressure prices downward, especially in Medicaid and public programs.
Mid to Long Term (2026-2028):
- Market share shifts will continue to favor biosimilars.
- Price erosion could reach 50% of pre-expiration levels, bringing average monthly prices below $3,500.
- New formulations or delivery methods may slightly mitigate price declines but are unlikely to offset biosimilar impact.
Revenue Forecast Assumptions:
- 2024: $15 billion global sales.
- 2025: Decline to ~$12 billion.
- 2026-2028: Stabilization around $8-10 billion annually, assuming biosimilar dominance.
Key Risks and Considerations
- Regulatory policies: Favorable policies promoting biosimilar uptake will accelerate price erosion.
- Patent litigations: Could delay biosimilar market penetration.
- Market acceptance: Physician and patient acceptance of biosimilars varies by country.
Summary Table: Price and Market Trends (2023-2028)
| Year |
Estimated Avg. Price (U.S., per month) |
Biosimilar Market Penetration |
Estimated Global Sales |
| 2023 |
$6,843 (pre-biosimilar) |
0% |
$20.7B |
| 2024 |
~$6,000 |
10-20% |
$15B |
| 2025 |
~$5,500 |
20-30% |
$12B |
| 2026 |
~$4,000-$4,500 |
40-50% |
$8-10B |
| 2027 |
~$3,500-$4,000 |
50-60% |
$8-10B |
| 2028 |
~$3,000-$3,500 |
60-70% |
$8-10B |
Key Takeaways
- Humira’s peak sales of over $20 billion are diminishing due to biosimilar competition.
- Price erosion of 50-60% is projected from 2023 levels over the next 4-5 years.
- Biosimilar adoption will accelerate in 2024, driven by regulatory policies and market dynamics.
- Long-term revenues are likely to stabilize significantly below pre-expiration levels.
FAQs
1. How much will the price of Humira decline due to biosimilars?
Estimated decline of 50-60% from 2023 list prices by 2028.
2. Which biosimilars are competing with Humira?
Amgen’s Amjevita and Samsung Bioepis’s Hadlima launched in late 2023.
3. Will branded Humira maintain profitability?
Profitability decreases as biosimilar sales increase and prices decline; margins will compress significantly.
4. How much market share do biosimilars hold by 2025?
Expected to reach 20-30%, with continued growth through 2028.
5. What policies could affect future pricing?
Legislative efforts promoting biosimilar substitution, patent litigation, and reimbursement policies.
References
- IQVIA. (2022). Global Healthcare Markets Report.
- U.S. Food and Drug Administration. (2023). Biosimilar Approval Data.
- AbbVie. (2023). Humira Sales Reports.
- Statista. (2023). Biologics Market Share and Pricing Trends.
- GoodRx. (2023). Humira Price Comparison and Biosimilar Impact.
